NASDAQ$ASRT

Assertio Holdings Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Assertio's Q3 2023 results were impacted by the loss of Indocin exclusivity and Rolvedon's underperformance, but the non-personal platform drove profitable growth on other assets.

Assertio Holdings reported disappointing Q3 2023 financial results, primarily due to the loss of Indocin exclusivity and lower-than-expected Rolvedon results. Net product sales increased slightly year-over-year, but the company experienced a significant net loss due to a charge for loss on impairment of intangible assets. Despite these challenges, the non-personal platform continues to drive growth for other assets like Sympazan and Otrexup.

  • Net product sales increased to $35.1 million from $34.3 million year over year.
  • A charge of $238.8 million was recorded for loss on impairment of intangible assets.
  • Cash and cash equivalents totaled $76.9 million at the end of the quarter.
  • Adjusted EBITDA decreased to $12.9 million from $21.4 million in the prior year quarter.

Headline financials

Total Revenue

$35.6M

Previous: $34.2M+4.1%
EPS (adj)

$0.01

Previous: $0.22-95.5%
Gross Margin

80.0%

No prior period
Capital Expenditures

-$528K

No prior period
Free Cash Flow

-$280M

Previous: $4.17M-6809.9%
Net Income

-$280M

Previous: $4.17M-6797.3%
Operating Income

-$228M

Previous: $6.43M-3647.9%
Gross Profit

-$7.06M

Previous: -$4.01M-76.1%
Cash & Equivalents

$76.9M

Previous: $64.8M+18.6%
Total Assets

$380M

Previous: $323M+17.5%
R&D Expense

$1.32M

No prior period
Stock-Based Comp

$1.87M

Previous: $2.4M-22.3%

Revenue & EPS history

Assertio · Revenue · Quarterly

$35.6M

Q3 2023+4.1%vs Q3 2022
Beat estimate in 11 of 14 quarters(79%)
ActualEstimate

Revenue by segment

Assertio · $40.1M total across 1 segment · Q2 2023

  • Net Product Sales
    $40.1M

Forward guidance

No specific forward guidance is provided in the document.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-1.9%

Avg return

Earnings day

-4.4%

Avg return

5 days after

-4.5%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+33.3%

Q3 2021

Best reaction

-46.2%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.5%+4.2%+4.7%
Q4 2025+6.5%+13.6%+53.1%
Q3 2025+13.3%-1.2%-1.2%
Q1 2025-1.8%+8.1%+0.0%
Q4 2024-7.5%-7.7%-20.5%
Q3 2024+0.2%-4.7%+12.9%
Q2 2024-12.8%-14.4%+0.8%
Q1 2024+7.8%-6.8%-2.9%
Q4 2023+10.8%+23.1%-1.1%
Q3 2023-45.5%-53.2%-50.9%
Q2 2023-46.2%-41.0%-39.0%
Q1 2023+20.6%+22.2%-3.8%
Q4 2022+7.9%-15.1%-0.6%
Q3 2022-0.4%+10.4%+38.1%
Q2 2022-4.3%-4.8%-32.6%
Q1 2022+6.2%+37.5%+52.9%
Q4 2021+13.8%-0.5%+56.9%
Q3 2021+33.3%+36.0%+18.4%
Q2 2021-2.3%-3.1%-16.3%
Q1 2021+11.8%-3.9%-11.8%
Q4 2020+4.3%-3.2%-35.1%
Q3 2020-41.8%-40.3%-37.3%
Q2 2020-13.8%-18.1%-23.4%
Q1 2020+1.3%+1.2%+21.3%
Q4 2019-35.1%-29.8%-37.7%
Q3 2019-9.6%-13.3%-14.5%
Q2 2019+1.4%-45.1%-54.2%
Q1 2019-0.4%-10.8%-37.9%
Q4 2018-5.8%-12.7%+26.8%
Q3 2018+6.5%+5.5%-16.3%
Q2 2018-19.0%-23.0%-33.5%
Q1 2018+26.5%+23.5%+10.6%
Q4 2017-11.4%-12.3%-15.0%
Q3 2017+15.4%+30.0%+68.6%
Q2 2017-35.1%-33.3%-37.4%
Q1 2017+2.3%+9.0%-3.1%
Q4 2016+4.7%-0.9%-9.9%
Q3 2016-16.1%-8.0%-12.1%
Q2 2016+5.6%+10.2%+8.7%
Q1 2016-6.2%
Q4 2015-4.1%
Q3 2015+6.7%
Q2 2015-7.2%
Q1 2015-14.1%
Q4 2014+13.4%
Q3 2014-2.7%
Q2 2014+5.5%
Q1 2014-23.5%
Q4 2013+14.8%
Q3 2013-0.5%
Q2 2013+4.0%
Q1 2013-2.8%
Q4 2012+6.2%
Q3 2012+1.5%
Q2 2012-0.5%
Q1 2012+3.2%
Q4 2011+3.3%
Q3 2011-10.4%
Q2 2011+3.1%
Q1 2011-1.2%
Q4 2010+0.6%
Q3 2010-0.2%
Q2 2010+5.2%
Q1 2010-4.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro